Proteome Sciences (LON:PRM) Shares Down 17.8% – Time to Sell?

Proteome Sciences plc (LON:PRM)’s stock price traded down 17.8% during mid-day trading on Monday . The company traded as low as GBX 1.51 and last traded at GBX 1.89. 160,218 shares traded hands during trading, a decline of 35% from the average session volume of 247,778 shares. The stock had previously closed at GBX 2.30.

Proteome Sciences Stock Performance

The company has a debt-to-equity ratio of -258.66, a quick ratio of 0.37 and a current ratio of 0.20. The firm’s 50 day moving average is GBX 2.49 and its 200-day moving average is GBX 2.87. The firm has a market cap of £4.46 million, a price-to-earnings ratio of -1.34 and a beta of 0.07.

Proteome Sciences (LON:PRM) last announced its earnings results on Thursday, September 25th. The company reported GBX (0.73) EPS for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.